import React from 'react';
import Image from "next/image";


function SectionThree() {
  return (
    
<>
       
    <article className=" shadow-lg rounded-xl p-8 mb-8">
      <header className="mb-6">
        <h1 className="text-3xl font-bold mb-2">Introduction</h1>
        {/* <div className="text-gray-600 text-lg">
          <span className="mr-2">John Doe</span>
        </div> */}
      </header>
      <div className="text-gray-800 leading-relaxed text-lg">

        <p> •Chemotherapy: Interfere with the cell cycle or DNA synthesis, leading to cell death or inhibition of cancer cell proliferation.
 </p>


        <p>•Targeted therapy: Block specific molecules or pathways involved in cancer growth and progression, such as receptor tyrosine kinases or growth factor receptors.
</p>


        <p> •Immunotherapy: Enhance the immune system's ability to recognize and destroy cancer cells, often by targeting immune checkpoints or cancer-specific antigens.
</p>


      </div>
      <br></br>
      <div className="text-gray-800 leading-relaxed text-lg">

      </div>
      <br />
      <br />
      <br />
      <header className="mb-6">
        <h1 className="text-3xl font-bold mb-2">MOAs</h1>
        {/* <div className="text-gray-600 text-lg">
          <span className="mr-2">John Doe</span>
        </div> */}
      </header>
      <div className="flex gap-4">
      <div className="rounded-lg border p-6  max-w-sm">
        <div className="p-4 rounded-lg bg-gray-100 dark:bg-gray-950">


          <p className="text-sm font-semibold leading-none ">
              Various cancers (breast cancer, lung cancer, leukemia, etc.).

              </p>


        </div>
      </div>
      <div className="rounded-lg border p-6 max-w-sm">
        <div className="p-4 rounded-lg bg-gray-100 dark:bg-gray-950">


          <p className="text-sm font-semibold leading-none">Examples: Paclitaxel, doxorubicin, imatinib, tamoxifen. </p>


        </div>
      </div>
    </div>
    <br />
      <div className="text-gray-800 leading-relaxed text-lg">
        
        <p> 1.&nbsp;&nbsp; alk_inhibitor
<br></br>
            2.&nbsp;&nbsp;aurora_kinase_inhibitor
<br></br>
            3.&nbsp;&nbsp;bcr-abl_inhibitor
<br></br>
            4.&nbsp;&nbsp;egfr_inhibitor
<br></br>
            5.&nbsp;&nbsp;flt3_inhibitor
<br></br>
            6.&nbsp;&nbsp;hcv_inhibitor
<br></br>
            7.&nbsp;&nbsp;mtor_inhibitor
<br></br>
            8.&nbsp;&nbsp;proteasome_inhibitor
<br></br>
            9.&nbsp;&nbsp;raf_inhibitor
<br></br>
            10.&nbsp;&nbsp;ras_gtpase_inhibitor
<br></br>
            11.&nbsp;&nbsp;topoisomerase_inhibitor
<br></br>
            12.&nbsp;&nbsp; tyrosine_kinase_inhibitor
<br></br>
          </p>
      </div>
      <br />
      <br />
      <br />
      <header className="mb-6">
        <h1 className="text-3xl font-bold mb-2">Drugs</h1>
        {/* <div className="text-gray-600 text-lg">
          <span className="mr-2">John Doe</span>
        </div> */}
      </header>
    <br />
      <div className="grid md:grid-cols-2 gap-4 bg-gray-100 text-lg ">
      <div className="border rounded-lg overflow-hidden">
        <table className="w-full ">
          <thead>
            <tr>
            </tr>
          </thead>
          <tbody className=''>
            <tr className="border-b ">
              <td className="px-4 py-3">1. Paclitaxel
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">2. Carboplatin
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">3. Cisplatin

</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">4. Doxorubicin
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">5. Methotrexate
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">6. Tamoxifen

</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">7. Imatinib

</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">8. Rituximab
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">9. Trastuzumab

</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">10. Gefitinib

</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">11. Erlotinib

</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">12. Bevacizumab
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">13. Vinblastine
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">14. Vincristine
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">15. Bortezomib
</td>
            </tr>
          </tbody>
        </table>
      </div>
      <div className="border rounded-lg overflow-hidden">
        <table className="w-full">
          <thead>
            <tr>
            </tr>
          </thead>
          <tbody>
            <tr className="border-b">
              <td className="px-4 py-3">16. Erlotinib</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">17. Trastuzumab
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">18. Panitumumab
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">19. Dasatinib</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">20. Nivolumab</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">21. Pembrolizumab</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">22. Abemaciclib
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">23. Alectinib
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">24. Olaparib</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">25. Enzalutamide
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">26. Palbociclib
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">27. Ribociclib
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">28. Ibrutinib</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">29. Venetoclax
</td>
            </tr>
            <tr className="border-b">
              <td className="px-4 py-3">30. Trifluridine/tipiracil
</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
      <br />
      <br />
      <br />
      <header className="mb-6">
        <h1 className="text-3xl font-bold mb-2"> Antineoplastic/Anticancerdiseases </h1>
        {/* <div className="text-gray-600 text-lg">
          <span className="mr-2">John Doe</span>
        </div> */}
      </header>
    <br />
      <div className="text-gray-800 leading-relaxed text-lg">
        
              <div className="text-gray-800 leading-relaxed text-lg">
        
        <p> •Breast cancer: A malignant tumor that develops in the breast tissue, which may include invasive ductal carcinoma, invasive lobular carcinoma, or other subtypes.
</p>
        <p>•Lung cancer: A malignancy arising from the lung tissue, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), often associated with smoking.
</p>
        <p>•Leukemia: Cancer of the blood-forming tissues, characterized by the overproduction of abnormal white blood cells (leukocytes), including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
</p>
        <p>•Lymphoma: Cancer of the lymphatic system, including Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma, characterized by the abnormal growth of lymphocytes.
</p>
       </div>
       <br />
       
       <div className="grid md:grid-cols-2 md:gap-6">
      <div className="border bg-gray-100 dark:bg-gray-950 p-4 rounded-lg space-y-4 mr-2">
        <h3 className="text-lg font-bold">Most Dangerous</h3>


        <p className="text-sm text-black leading-normal">
          • Pancreatic cancer: Pancreatic cancer has one of the lowest survival rates among cancers, often due to late diagnosis and aggressive tumor behavior. It tends to spread rapidly and is frequently diagnosed at an advanced stage, making it difficult to treat effectively.

        </p>


      </div>
      <div className="border  rounded-lg  bg-gray-100 dark:bg-gray-950 p-4 space-y-4 ">
        <h3 className="text-lg font-bold">Most Widespread</h3>


        <p className="text-sm text-black leading-normal">
          • Lung cancer: Lung cancer is one of the most prevalent cancers globally and a leading cause of cancer-related deaths. It is closely associated with tobacco smoking but can also occur in non-smokers due to other factors such as exposure to secondhand smoke, air pollution, or occupational hazards.

        </p>


      </div>
    </div>
       </div>
       <br />
      <br />
            <h2  className="text-lg font-semibold leading-none">
              Examples of where finding effective treatments or cures presents significant challenges:
            </h2>
 
        <br />
        <div className="text-gray-800 leading-relaxed text-lg">



         <p>•Glioblastoma multiforme (GBM): GBM is an aggressive form of brain cancer with a poor prognosis and limited treatment options. Despite extensive research efforts, including surgery, radiation therapy, and chemotherapy with drugs like temozolomide, the median survival for patients with GBM remains relatively short. The highly invasive nature of GBM tumors, along with their ability to evade treatment and recur, presents significant challenges in developing effective therapies. Additionally, the blood-brain barrier limits the delivery of drugs to the brain, further complicating treatment strategies for GBM.
 </p>


        </div>

    </article>
</>
  );
}

export default SectionThree;
